BSX stock forecast, quote, news & analysis
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts... Show more
Why Boston Scientific (BSX) Stock Is Down -20.3% in the Last 30 Days
Key Takeaways
- Boston Scientific (BSX) shares fell approximately 20.3% over the last 30 days, dropping from $56.81 on May 19, 2026, to $45.29 on June 18, 2026.
- The quarterly decline is even steeper at roughly 36%, with the stock sliding from $71.28 in mid-March amid a broader medtech sector selloff.
- Weakening growth in the flagship WATCHMAN FLX left atrial appendage closure device and cut FY2026 guidance have been the primary drags on investor sentiment.
- Multiple Wall Street analyst downgrades and sharp price target reductions accelerated the downward momentum throughout late May and June.
- A $2 billion accelerated share repurchase and a $1.5 billion strategic investment in MiRus provided brief support but failed to offset macro and competitive headwinds.
- Despite the selloff, the majority of analysts maintain Buy ratings, with an average 12-month price target near $77, reflecting a wide disconnect between near-term pessimism and long-term fundamentals.
Boston Scientific (BSX) Company Overview and Market Position
Boston Scientific Corporation is a global developer, manufacturer, and marketer of minimally invasive medical devices used across a broad range of interventional medical specialties. Headquartered in Marlborough, Massachusetts, the company operates through two primary segments: MedSurg (Endoscopy, Urology, and Neuromodulation) and Cardiovascular (Cardiology and Peripheral Interventions). Its portfolio includes industry-leading products such as the WATCHMAN FLX left atrial appendage closure device, the FARAPULSE pulsed field ablation system, implantable cardiac rhythm management devices, and a comprehensive line of endoscopy and urology solutions. With approximately 59,000 employees and trailing 12-month revenue exceeding $20.6 billion, Boston Scientific ranks among the largest pure-play medical device companies globally, competing alongside peers like Medtronic, Abbott Laboratories, and Stryker.
Boston Scientific (BSX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 calendar days, BSX shares declined from an adjusted closing price of $56.81 on May 19, 2026, to $45.29 on June 18, 2026 — a drop of approximately 20.3%. The decline accelerated sharply in the final week of May, with the stock suffering a single-day plunge of 12.5% on May 27 following the Bernstein Strategic Decisions Conference, where CEO Michael Mahoney detailed unanticipated headwinds affecting the company's full-year outlook. The selling pressure continued through June, with the stock hitting a 52-week low of $44.44 on June 18.
Zooming out to the full quarter, the performance is even more pronounced. From a closing price of $71.28 on March 18, 2026, BSX has fallen roughly 36%. The quarterly decline reflects a confluence of factors: a Q1 earnings report that beat estimates but included a guidance cut, mounting evidence of slowing WATCHMAN adoption, intensifying competitive threats in electrophysiology from Johnson & Johnson, and a broader rotation away from medtech stocks that had previously traded at premium valuations.
What Drove BSX Stock Price in the Last 30 Days
The most significant catalyst during the past 30 days was the fallout from Boston Scientific's appearance at the Bernstein 42nd Annual Strategic Decisions Conference on May 27. CEO Michael Mahoney outlined three unanticipated factors that forced the company to trim its fiscal 2026 guidance, including slower-than-expected WATCHMAN FLX adoption rates, competitive encroachment in the U.S. electrophysiology market, and macroeconomic pressures affecting hospital capital spending. The stock dropped 12.5% in a single session on record-high volume of over 52 million shares.
This event triggered a wave of analyst actions. Wolfe Research downgraded BSX from Outperform to Peer Perform, citing faltering key growth drivers. Wells Fargo cut its rating from Overweight to Equal Weight, explicitly pointing to the WATCHMAN slowdown. Piper Sandler slashed its price target from $90 to $65, BofA reduced its target from $68 to $61, and Truist, BTIG, TD Cowen, and Citigroup all followed with significant target reductions. These downgrades compounded the negative sentiment and fueled additional selling pressure throughout early June.
On the positive side, Boston Scientific announced a $2 billion accelerated share repurchase agreement and a $1.5 billion strategic equity investment in MiRus LLC, a developer of next-generation transcatheter aortic valve replacement technology, on May 18. The SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter also met all primary safety and effectiveness endpoints in the FRACTURE IDE trial. However, these developments were overshadowed by the guidance concerns and the broader medtech sector downturn.
What Drove BSX Stock Performance Over the Last Quarter
The quarterly decline of approximately 36% reflects a narrative that began shifting in late March and intensified through April and May. The Q1 2026 earnings report on April 22 exemplified the mixed signals: Boston Scientific delivered a top- and bottom-line beat with revenue of $5.2 billion and EPS of $0.80 versus estimates of $0.79, yet management simultaneously reduced full-year 2026 guidance. The initial 9% rally on earnings day proved short-lived as investors digested the implications of slowing growth in the company's highest-profile product lines.
Competitive dynamics also weighed heavily. Johnson & Johnson launched an improved Shockwave intravascular lithotripsy catheter and initiated a head-to-head pulsed field ablation trial directly comparing its device against Boston Scientific's FARAPULSE system. Additionally, a securities fraud class action lawsuit was filed alleging that executives misrepresented U.S. electrophysiology volumes, adding legal uncertainty to the investment narrative. The combination of fundamental concerns, competitive threats, legal overhang, and a broader sector rotation out of high-multiple medtech names created a powerful downward current that carried BSX from above $70 in March to the mid-$40s by mid-June.
Trending AI Robots
In volatile market environments like the one currently affecting Boston Scientific, traders increasingly turn to data-driven tools to navigate price swings. Tickeron's Trending AI Robots page offers a curated selection of top-performing AI-powered trading bots from a universe of hundreds that actively trade thousands of tickers. These bots employ diverse strategies — ranging from short-term momentum plays to longer-duration trend-following approaches — and are ranked by verified performance metrics. Only the most relevant and consistently profitable bots appear in this section, providing traders with a transparent window into algorithmic trading strategies that have demonstrated real-world results. Exploring the Trending AI Robots page can help investors identify AI-driven approaches that align with their own trading objectives and risk tolerance.
BSX Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most critical event on the calendar is Boston Scientific's second-quarter 2026 earnings report, scheduled for July 29. Investors will scrutinize whether WATCHMAN FLX adoption trends have stabilized, whether electrophysiology market share is holding against competitive incursions, and whether management reaffirms or further adjusts full-year guidance. The $2 billion accelerated share repurchase program should provide some support to earnings per share, but its impact on stock price will depend heavily on the fundamental narrative.
Additional factors to monitor include the progress of the MiRus investment and its implications for Boston Scientific's structural heart portfolio, data readouts from ongoing clinical trials including the CHAMPION-AF and HI-PEITHO studies, and any resolution or escalation of the securities class action litigation. Macroeconomic conditions — particularly hospital capital budgets, interest rate policy, and healthcare utilization trends — will continue to influence the entire medtech sector. With analyst price targets still averaging around $77 despite the recent cuts, the gap between Wall Street's long-term expectations and current market pricing remains unusually wide, making upcoming earnings and guidance updates pivotal for the stock's trajectory.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BSX in upward trend: price may jump up because it broke its lower Bollinger Band on June 22, 2026
BSX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 36 cases where BSX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 21 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for BSX just turned positive on June 23, 2026. Looking at past instances where BSX's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BSX advanced for three days, in of 341 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on May 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BSX as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BSX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for BSX entered a downward trend on June 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.548) is normal, around the industry mean (10.755). P/E Ratio (18.548) is within average values for comparable stocks, (61.580). Projected Growth (PEG Ratio) (0.537) is also within normal values, averaging (3.711). BSX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.018). P/S Ratio (3.214) is also within normal values, averaging (23.791).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BSX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of medical devices
Industry MedicalNursingServices